Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

FDA Approval

FDA Approves Daraxonrasib for Advanced Pancreatic Cancer

The move could expand treatment options for people with RAS‑driven tumours.

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

FDA Clears First Broadly RAS‑Targeting Pill for Advanced Pancreatic Cancer

FDA Expands Approval of J&J’s Imaavy to Treat Warm Autoimmune Hemolytic Anemia

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

FDA Approves Bizengri for NRG1 Fusion Cholangiocarcinoma Under Accelerated Pathway

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

FDA Clears Dupixent as First Biologic for Young Children With Chronic Spontaneous Urticaria

GLP-1 Pills Accelerate into U.S. Care with Amazon Rollout and New Evidence on Use and Response

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral Wegovy Weight-Loss Pill as U.S. Availability Begins

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Novo Nordisk Launches Ozempic in India With Weekly Starting Price of ₹2,200

FDA Fast-Tracks Augmentin XR in First Approval Under National Priority Voucher Pilot

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy